Market Mover | Mesoblast Shares Hit Four-Year High After Receiving US FDA Approval for Mesenchymal Stromal Cell Therapy
Market Mover | Mesoblast Shares Hit Four-Year High After Receiving US FDA Approval for Mesenchymal Stromal Cell Therapy
市場動向 | Mesoblast 股票在獲得美國FDA對間充質幹細胞療法的批准後達到四年新高
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間